1.07
1.07 (0%)
As of Feb 14, 2025
Clearside Biomedical, Inc. [CLSD]
Source:
Company Overview
Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, or SCS. Our novel SCS injection platform, utilizing our proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
| Country | United States |
| Headquarters | alpharetta, georgia |
| Phone Number | (678) 270-3631 |
| Industry | manufacturing |
| CEO | George Lasezkay, Pharm.D., J.D. |
| Website | www.clearsidebio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.7 |
| Operating Profit | $-28.9 |
| Net Income | $-34.4 |
| Net Cash | $-8.9 |
Profit Ratios
| Gross Margin | $1.5 |
| Operating Margin | -1,735.7 |
| Profit as % of Revenues | -4.4% |
| Profit as % of Assets | -116.2% |
| Profit as % of Stockholder Equity | 88.4% |
Management Effectiveness
| Return on Equity | 88.4% |
| Return on Assets | -136.7% |
| Turnover Ratio | 5.6% |
| EBITA | $-28.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $25.1 |
| Total Liabilities | $64 |
| Operating Cash Flow | $-24.7 |
| Investing Cash Flow | $-0.6 |
| Financing Cash Flow | $16.4 |
